Rare
lephants
Screener
Toggle theme
Harmony Biosciences Holdings, Inc.
HRMY
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
Total Cash from Operations:
$348.2M
Line Item
Value
% of Total
Capital Expenditures
$0
0.0%
Other Investing
$0
0.0%
Other Financing
$9.0M
2.6%
Other
$39.6M
11.4%
Net Cash Flow
$299.5M
86.0%
Download CSV
